Connect with us


AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) Unveils its NeuCovix™ Test That Can Accurately Classify COVID-19 Neutralization Tests



AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has completed a study focusing on the performance of its NeuCovix™ rapid test measuring the neutralizing levels of anti-COVID-19 antibodies.

NeuCovix™ accurately categorizes blood serum

The company compared the NeuCovix™ with the pseudovirus-based gold standard test. Results indicated that the NeuCovix™ test precisely categorized serum form COVID-19 patients that had strongly neutralized the SARS-CoV-2 as well as serum from those that had neutralized the virus poorly. Interestingly there was no cross-reaction with serum for the NeuCovix™ test for patients with seasonal respiratory infections that include seasonal coronavirus, which is an indication that the test has almost 100% specificity for SARS-CoV-2.

The current tests that use live viruses are expensive, time-consuming, and need highly trained personnel working in a tightly managed lab environment in measuring neutralizing antibodies. On the other hand, the NeuCovix™ test is cheap, portable, and quick point-of-care tests that determine the neutralizing antibody level in less than ten minutes. Considering the NeuCovix™ tests are in line with virus assay, it could prove to be an effective and affordable tool in monitoring huge numbers of subjects receiving vaccines for antibody neutralizing.

NeuCovix™ test is faster and less expensive

Also, NeuCovix™ can be used in measuring neutralizing antibodies levels in patients under that are receiving convalescent plasma or hyperimmune globulin to enable healthcare providers to determine the ideal neutralizing antibodies dosing that is in line with favorable results. John Huemoeller II, the CEO of AXIM® Biotech, stated that they were delighted with the preliminary test results showed by NeuCovix™. He added that the difference the tests deliver in time of money and time for vaccine developers and blood centers is huge.

AXIM® Biotech’s wholly-owned subsidiary, Sapphire Biotech’s Chief Scientific Officer Sergei Svarovusky, said that there is still work that needs to be done EUA. Sergei said that the 10-minute test has shown almost similar protective immune outcomes in samples of plasma from patients with high and low titers compared to the other time consuming and expensive lab tests.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.